Related coverage linked through entity extraction aliases.
Mar 04, 2026
Oncology specialists are warning cancer patients against biotin supplementation, citing its capacity to distort critical laboratory test results including hormone panels used to monitor treatment and detect recurrence.
Feb 28, 2026
Johnson & Johnson stock hit an all-time high of $246.54, up 54.05% over the past year. The company announced a $1 billion investment in a Pennsylvania cell therapy facility and received upgraded price targets from major financial firms.
Feb 20, 2026
Barclays initiated coverage on Merck with an overweight rating and $140 price target, citing expected product launches including enlicitide and pivotal trial readouts for tulisokibart in 2026.
Feb 17, 2026
Oncolytics Biotech received FDA Fast Track Designation for pelareorep in second-line KRAS-mutant microsatellite-stable metastatic colorectal cancer, based on clinical data showing a 33% response rate and median overall survival of 27 months versus 11.2 months with standard treatment.
Feb 16, 2026
Oncolytics Biotech received FDA Fast Track Designation for pelareorep in second-line KRAS-mutant microsatellite-stable metastatic colorectal cancer, based on clinical data showing a 33% response rate and median survival of 27 months versus 11.2 months with standard treatment.
Feb 16, 2026
CStone Pharmaceuticals has received FDA clearance for its IND application to initiate a Phase II trial of CS2009, a trispecific antibody targeting PD-1, VEGFA, and CTLA-4, in patients with advanced solid tumors across nine cancer indications.
Feb 14, 2026
A Philadelphia jury found Johnson & Johnson liable for a woman's ovarian cancer death linked to talc-based baby powder, awarding $250,000 in damages. The verdict marks the first plaintiffs' win in Philadelphia's talc mass tort litigation.
Feb 14, 2026
Homologous recombination deficiency testing and molecular profiling are reshaping treatment strategies for advanced ovarian cancer, guiding PARP inhibitor and bevacizumab maintenance decisions in newly diagnosed patients.
Feb 13, 2026
Merck stock reached a 52-week high at $122.69, rising 46.25% over 12 months and 7.4% in the past month following strong Q4 results and improved long-term pipeline outlook beyond Keytruda's 2028 patent expiration.
Sep 11, 2025
The FDA issued a Complete Response Letter for Corcept's relacorilant as a treatment for hypertension secondary to hypercortisolism, requesting additional evidence of effectiveness despite acknowledging positive trial results.
